Unleash Immuno Oncolytics, Inc.

ST. LOUIS, MO · Founded 2015 · CIK 0001732374 · Biotech · Acquired

Armed oncolytic virus that targets cancer stroma to activate anti-tumor immune responses

unleash.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.0M
1 Form D · Feb 2018
104 months since last filing
Contracts
—
No federal contracts on record
Patents
6
1 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1172SCYNEXIS, INC.—$5.5M
1173MediSix Therapeutics, Inc.—$35M
1174ISOThrive Inc.—$17M
1175Unleash Immuno Oncolytics, Inc.—$3.0M
1176Cessation Therapeutics, Inc.—$6.8M
1177Dnalite Therapeutics, Inc.—$5.6M
1178Xenon Pharmaceuticals——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Ricardo Lisandro BrilDirector
  • Bolten CharlesDirector
  • Daniel KatzmanDirector · Executive Officer
  • Ariel MusleraDirector

Patents

USPTO · 1 granted of 6
  • Oncolytic Adenoviral Vector And Methods Of Useapplication
  • Oncolytic Adenoviral Vector And Methods Of Usegranted
  • Oncolytic Adenoviral Vector And Methods Of Useapplication
  • Oncolytic Adenoviral Vector And Methods Of Use Incorporation-by-reference Of Material Submitted Electronicallyapplication
  • Oncolytic Adenoviral Vector And Methods Of Useapplication
  • Oncolytic Adenoviral Vector And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.